uniQure (NASDAQ:QURE) Shares Up 3.9% – Here’s Why

uniQure (NASDAQ:QURE) shares were up 3.9% during mid-day trading on Tuesday . The stock traded as high as $9.66 and last traded at $9.53. Approximately 71,205 shares traded hands during trading, a decline of 96% from the average daily volume of 1,676,247 shares. The stock had previously closed at $9.17.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on QURE. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. StockNews.com upgraded uniQure to a “sell” rating in a research report on Tuesday, March 11th. Wells Fargo & Company dropped their price target on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of uniQure in a report on Tuesday, March 4th. Finally, Stifel Nicolaus increased their price target on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, uniQure has a consensus rating of “Moderate Buy” and a consensus target price of $38.80.

uniQure Stock Up 3.4 %

The business’s fifty day moving average price is $12.14 and its two-hundred day moving average price is $11.14. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm has a market capitalization of $512.65 million, a P/E ratio of -1.91 and a beta of 0.42.

Insider Buying and Selling at uniQure

In other uniQure news, CFO Christian Klemt sold 10,438 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the sale, the chief financial officer now directly owns 217,730 shares of the company’s stock, valued at $2,240,441.70. This trade represents a 4.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 26,727 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $285,978.90. Following the transaction, the chief executive officer now owns 571,188 shares of the company’s stock, valued at approximately $6,111,711.60. This represents a 4.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is owned by corporate insiders.

Institutional Trading of uniQure

A number of large investors have recently modified their holdings of QURE. Charles Schwab Investment Management Inc. lifted its holdings in uniQure by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock worth $1,367,000 after buying an additional 16,464 shares during the last quarter. FMR LLC grew its position in shares of uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after buying an additional 346,274 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in uniQure in the third quarter valued at $283,000. Geode Capital Management LLC boosted its stake in uniQure by 1.3% in the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after acquiring an additional 6,362 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new stake in shares of uniQure in the 3rd quarter valued at about $7,360,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.